Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025
상품코드:1825476
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
비소세포폐암(NSCLC) 시장의 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 10.4%로 328억 8,000만 달러로 성장할 전망입니다. 예측기간의 성장은 새로운 병용요법, 인공지능(AI)의 통합, 개별화 백신의 확대, 세계적인 공동연구, 환자 중심의 의료에 기인할 것으로 전망됩니다. 예측기간의 주요 동향으로는 암의료와 원격의료의 통합, 액체 생검 기술, 진단 기술의 진보, 저침습 수술 기술의 채용, 면역관문억제제 등이 있습니다.
향후 5년간의 예측 성장률 10.4%는 과거 예측에서 0.1% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세장벽은 스위스나 일본에서 조달하는 PD-1/PD-L1 억제제나 액체 생검 키트의 비용을 상승시키고, 맞춤형 치료 계획을 지연시키며, 종양과의 지출을 증가시킴으로써 미국 시장을 저해할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.
담배 소비율의 상승이 향후 수년간 비소세포폐암(NSCLC) 시장의 성장을 견인할 것으로 예측됩니다. 담배 소비는 일반적으로 피우는 담배, 씹는 담배, 코담배 등 개인 담배 제품의 사용을 말하며, 니코틴 및 기타 화학물질을 체내에 흡수합니다. 담배 연기는 폐세포의 DNA(데옥시리보핵산)를 손상시키고 돌연변이와 비소세포폐암(NSCLC)을 포함한 암세포의 통제 불가한 증식으로 이어지는 수많은 발암성 물질이 포함되어 있습니다. 예를 들어 미국을 거점으로 하는 연방 정부기관인 미국 식품의약국(USFDA)이 발표한 2024년 전미 청소년 담배 조사에 따르면 2024년 10월 전 학생의 1.1%(약 225만명)가 현재 담배 제품을 사용하고 있다고 응답했습니다. 이 중 고등학생의 10.1%(약 158만명), 중학생의 5.4%(약 64만명)가 포함되어 있으며, 가연성 담배 제품 중 하나를 현재 사용하고 있다고 응답한 학생은 2.8%(약 76만명), 여러 담배 제품을 사용하고 있다고 응답한 학생은 3.0%(약 84만명)로 나타났습니다. 따라서 담배 소비율의 상승이 비소세포폐암(NSCLC) 시장의 성장을 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 비소세포폐암(NSCLC) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 비소세포폐암(NSCLC) 시장 : 성장률 분석
세계의 비소세포폐암(NSCLC) 시장 실적 : 규모와 성장(2019-2024년)
세계의 비소세포폐암(NSCLC) 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 비소세포폐암(NSCLC) : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 비소세포폐암(NSCLC) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
편평상피암
대세포암
선암
기타 유형
세계의 비소세포폐암(NSCLC) 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
방사선요법
레이저요법
광선역학요법(PDT)
기타 치료법
세계의 비소세포폐암(NSCLC) 시장 : 유통채널별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원 약국
온라인 약국
기타 유통채널
세계의 비소세포폐암(NSCLC) 시장 : 세분화 편평상피암(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
각화성 편평상피암
비각화성 편평상피암
세계의 비소세포폐암(NSCLC) 시장 : 세분화 대세포암(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
미분화 대세포암
대세포 신경내분비암
세계의 비소세포폐암(NSCLC) 시장 : 세분화 선암(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
침윤성 선암
세기관지 폐포암
세계의 비소세포폐암(NSCLC) 시장 : 세분화 기타 유형(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
혼합세포형 암
육종과 같은 암
제7장 지역별/국가별 분석
세계의 비소세포폐암(NSCLC) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 비소세포폐암(NSCLC) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
비소세포폐암(NSCLC) 시장 : 경쟁 구도
비소세포폐암(NSCLC) 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca plc
GlaxoSmithKline Plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Viatris Inc
Teva Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
UCB SA
Sun Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Aurobindo Pharma Limited
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
비소세포폐암(NSCLC) 시장(2029년) : 새로운 기회를 제공하는 국가
비소세포폐암(NSCLC) 시장(2029년) : 새로운 기회를 제공하는 부문
비소세포폐암(NSCLC) 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Non-small cell lung cancer (NSCLC) is a form of epithelial lung cancer that originates in the lung tissues, marked by the abnormal proliferation of cells. The primary causes of NSCLC include long-term smoking, genetic mutations, exposure to air pollution, and secondhand smoke.
The main subtypes of non-small cell lung cancer (NSCLC) are squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Squamous cell carcinoma originates from squamous epithelial cells and can manifest in various parts of the body. A variety of therapeutic approaches are employed for NSCLC, including radiotherapy, laser therapy, photodynamic therapy (PDT), and others. These therapeutic options are distributed through different channels, including hospital pharmacies, online pharmacies, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The non-small cell lung cancer (NSCLC) market research report is one of a series of new reports from The Business Research Company that provides non-small cell lung cancer (NSCLC) market statistics, including non-small cell lung cancer (NSCLC) industry global market size, regional shares, competitors with a non-small cell lung cancer (NSCLC) market share, detailed non-small cell lung cancer (NSCLC) market segments, market trends and opportunities, and any further data you may need to thrive in the non-small cell lung cancer (NSCLC) industry. This non-small cell lung cancer (NSCLC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-small cell lung cancer (nsclc) market size has grown rapidly in recent years. It will grow from $20.1 billion in 2024 to $22.14 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to evolution of immunotherapy, genomic profiling and precision medicine, expansion of clinical trials, smoking cessation initiatives.
The non-small cell lung cancer (nsclc) market size is expected to see rapid growth in the next few years. It will grow to $32.88 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to emerging combination therapies, integration of artificial intelligence (AI), expansion of personalized vaccines, global collaborations in research, patient-centric care. Major trends in the forecast period include integration of telemedicine in oncology, liquid biopsy technologies, advances in diagnostic technologies, adoption of minimally invasive surgical techniques, immune checkpoint inhibitors.
The forecast of 10.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of PD-1/PD-L1 inhibitor drugs and liquid biopsy kits sourced from Switzerland and Japan, thereby delaying personalized treatment plans and elevating oncology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising rate of tobacco consumption is anticipated to drive the growth of the non-small cell lung cancer (NSCLC) market in the coming years. Tobacco consumption refers to individuals' use of tobacco products, commonly through smoking, chewing, or snuffing, which introduces nicotine and other chemicals into the body. Tobacco smoke contains numerous carcinogens that can damage DNA (deoxyribonucleic acid) in lung cells, leading to mutations and the uncontrolled growth of cancerous cells, including non-small cell lung cancer (NSCLC). For instance, according to the 2024 National Youth Tobacco Survey published by the U.S. Food and Drug Administration (USFDA), a U.S.-based federal agency, in October 2024, 1.1% of all students (around 2.25 million) reported current tobacco product use. This included 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (about 640,000) who reported using tobacco; additionally, 2.8% of students (around 760,000) reported current use of any combustible tobacco product, while 3.0% (about 840,000) reported using multiple tobacco products. Consequently, the rising rate of tobacco consumption is fueling growth in the non-small cell lung cancer (NSCLC) market.
The anticipated growth of the non-small cell lung cancer (NSCLC) market is further driven by increasing air pollution. Harmful substances in the atmosphere, constituting air pollution, can adversely affect human health, increasing the risk of NSCLC through inflammation, DNA damage, and mutations in lung cells. The World Health Organization reported in June 2023 that air and household air pollution were linked to 7 million premature deaths annually. Additionally, approximately 2.4 billion people are exposed to dangerous levels of household air pollution. The World Bank further highlighted in September 2022 that health damage from air pollution amounts to $8.1 trillion annually, equivalent to 6.1% of global GDP. Thus, the growth of non-small cell lung cancer (NSCLC) is expected to be propelled by increasing air pollution.
Major companies in the non-small cell lung cancer (NSCLC) market are strategically developing multiple treatment options, including monotherapy treatments, to gain a competitive advantage. Monotherapy treatment, utilizing a single drug or therapy to address medical disorders, provides a focused approach. For instance, in June 2022, Novartis AG gained approval from the European Commission for Tabrecta (capmatinib) to treat adult patients with advanced NSCLC with METex14 skipping. This targeted therapeutic option addresses mutations causing MET exon 14 (METex14) skipping.
In August 2022, Bristol-Myers Squibb's acquisition of Turning Point Therapeutics for $4.1 billion enhances its ability to treat ROS1-positive NSCLC patients with the promising therapy, repotrectinib, developed by Turning Point Therapeutics. Repotrectinib holds the potential to improve outcomes for patients with ROS1-positive non-small-cell lung cancer. Turning Point Therapeutics specializes in developing precision medicines for NSCLC.
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (nsclc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the non-small cell lung cancer (nsclc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The non-small cell lung cancer (NSCLC) market includes revenues earned by entities by providing services such as targeted therapies, radiation therapies, imaging tests, biopsy, bronchoscopy, and lung function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-small cell lung cancer (NSCLC) market also includes sales of chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, afatinib, and gefitinib, as well as pain medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on non-small cell lung cancer (nsclc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-small cell lung cancer (nsclc) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-small cell lung cancer (nsclc) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
2) By Therapy: Radiotherapy; Laserthearpy; Photodynamic Therapy (PDT); Other Therapies
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Non-Small Cell Lung Cancer (NSCLC) Market Characteristics
3. Non-Small Cell Lung Cancer (NSCLC) Market Trends And Strategies
4. Non-Small Cell Lung Cancer (NSCLC) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Non-Small Cell Lung Cancer (NSCLC) Growth Analysis And Strategic Analysis Framework
5.1. Global Non-Small Cell Lung Cancer (NSCLC) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Small Cell Lung Cancer (NSCLC) Market Growth Rate Analysis
5.4. Global Non-Small Cell Lung Cancer (NSCLC) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Small Cell Lung Cancer (NSCLC) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Small Cell Lung Cancer (NSCLC) Total Addressable Market (TAM)
6. Non-Small Cell Lung Cancer (NSCLC) Market Segmentation
6.1. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Squamous Cell Carcinoma
Large Cell Carcinoma
Adenocarcinoma
Other Types
6.2. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Radiotherapy
Laserthearpy
Photodynamic Therapy (PDT)
Other Therapies
6.3. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Online Pharmacy
Other Distribution Channels
6.4. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Keratinizing Squamous Cell Carcinoma
Non-Keratinizing Squamous Cell Carcinoma
6.5. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Undifferentiated Large Cell Carcinoma
Large Cell Neuroendocrine Carcinoma
6.6. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Invasive Adenocarcinoma
Bronchioloalveolar Carcinoma
6.7. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mixed Cell Type Carcinoma
Sarcomatoid Carcinoma
7. Non-Small Cell Lung Cancer (NSCLC) Market Regional And Country Analysis
7.1. Global Non-Small Cell Lung Cancer (NSCLC) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Small Cell Lung Cancer (NSCLC) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market
8.1. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Non-Small Cell Lung Cancer (NSCLC) Market
9.1. China Non-Small Cell Lung Cancer (NSCLC) Market Overview
9.2. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Non-Small Cell Lung Cancer (NSCLC) Market
10.1. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Non-Small Cell Lung Cancer (NSCLC) Market
11.1. Japan Non-Small Cell Lung Cancer (NSCLC) Market Overview
11.2. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Non-Small Cell Lung Cancer (NSCLC) Market
12.1. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market
13.1. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Non-Small Cell Lung Cancer (NSCLC) Market
14.1. South Korea Non-Small Cell Lung Cancer (NSCLC) Market Overview
14.2. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market
15.1. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market Overview
15.2. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Non-Small Cell Lung Cancer (NSCLC) Market
16.1. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Non-Small Cell Lung Cancer (NSCLC) Market
17.1. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Non-Small Cell Lung Cancer (NSCLC) Market
18.1. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Non-Small Cell Lung Cancer (NSCLC) Market
19.1. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Non-Small Cell Lung Cancer (NSCLC) Market
20.1. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market
21.1. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market Overview
21.2. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Non-Small Cell Lung Cancer (NSCLC) Market
22.1. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Non-Small Cell Lung Cancer (NSCLC) Market
23.1. North America Non-Small Cell Lung Cancer (NSCLC) Market Overview
23.2. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Non-Small Cell Lung Cancer (NSCLC) Market
24.1. USA Non-Small Cell Lung Cancer (NSCLC) Market Overview
24.2. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Non-Small Cell Lung Cancer (NSCLC) Market
25.1. Canada Non-Small Cell Lung Cancer (NSCLC) Market Overview
25.2. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Non-Small Cell Lung Cancer (NSCLC) Market
26.1. South America Non-Small Cell Lung Cancer (NSCLC) Market Overview
26.2. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Non-Small Cell Lung Cancer (NSCLC) Market
27.1. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Non-Small Cell Lung Cancer (NSCLC) Market
28.1. Middle East Non-Small Cell Lung Cancer (NSCLC) Market Overview
28.2. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Non-Small Cell Lung Cancer (NSCLC) Market
29.1. Africa Non-Small Cell Lung Cancer (NSCLC) Market Overview
29.2. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Non-Small Cell Lung Cancer (NSCLC) Market Competitive Landscape And Company Profiles
30.1. Non-Small Cell Lung Cancer (NSCLC) Market Competitive Landscape
30.2. Non-Small Cell Lung Cancer (NSCLC) Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Non-Small Cell Lung Cancer (NSCLC) Market Other Major And Innovative Companies
31.1. Sanofi S.A.
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. GlaxoSmithKline Plc
31.5. Takeda Pharmaceutical Company Limited
31.6. Eli Lilly and Company
31.7. Amgen Inc.
31.8. Viatris Inc
31.9. Teva Pharmaceutical Industries Ltd.
31.10. Regeneron Pharmaceuticals Inc.
31.11. Astellas Pharma Inc.
31.12. UCB S.A.
31.13. Sun Pharmaceutical Industries Ltd.
31.14. Dr. Reddy's Laboratories Ltd.
31.15. Aurobindo Pharma Limited
32. Global Non-Small Cell Lung Cancer (NSCLC) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Non-Small Cell Lung Cancer (NSCLC) Market
34. Recent Developments In The Non-Small Cell Lung Cancer (NSCLC) Market
35. Non-Small Cell Lung Cancer (NSCLC) Market High Potential Countries, Segments and Strategies
35.1 Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Growth Strategies
